Fidelity Investments
AGRX

Fidelity Investments’s Agile Therapeutics AGRX Stock Holding History

Fidelity Investments’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$2 – 5772
2023
Q3 		$2 Buy
+1
New +$2 ﹤0.01% 5253
2023
Q1 		– Sell
-1
Closed -$13 – 5614
2022
Q4 		$11 Hold
1
– – ﹤0.01% 5227
2022
Q3 		$0 Hold
1
– – ﹤0.01% 5567
2022
Q2 		$0 Buy
+1
New +$145 ﹤0.01% 5674
2021
Q4 		– Hold
0
– – – 5136
2021
Q3 		– Hold
0
– – – 5256
2020
Q2 		– Hold
0
– – – 4322
2020
Q1 		– Hold
0
– – – 4402
2019
Q4 		– Hold
0
– – – 3710
2019
Q3 		– Hold
0
– – – 3704

Other funds holding AGRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Fidelity Investments's AGRX Position: Q4 2023 in Review

Fidelity Investments sold out of Agile Therapeutics (AGRX) in Q4 2023, closing a stake of 1 share — an estimated $2 sold.

Fidelity Investments first reported a position in AGRX in Q2 2022 and held it in 4 quarters. The position peaked at $11 in Q4 2022. 21 funds tracked by Wall St. Rank hold AGRX as of Q4 2023.

  • Fidelity Investments reported no remaining Agile Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Fidelity Investments sold 1 Agile Therapeutics share in Q4 2023, an estimated $2.
  • Fidelity Investments first reported a position in Agile Therapeutics in Q2 2022 and held it in 4 quarters.
  • Fidelity Investments's Agile Therapeutics position peaked at $11 in Q4 2022.
  • 21 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2023.

Based on Fidelity Investments's 13F filing for Q4 2023, filed 13 Feb 2024.